OrbiMed's Stake in Q32 Bio Diluted to 15.4% Following Recent Offering
Summary
OrbiMed Advisors and OrbiMed Capital GP VII LLC reported a decrease in their beneficial ownership of Q32 Bio Inc. to 15.4% due to an increase in the company's outstanding shares, reflecting the dilutive impact of a recent capital raise.
Key Events
-
Major Shareholder Stake Reduced
OrbiMed Advisors and OrbiMed Capital GP VII LLC now beneficially own 2,252,987 shares, representing 15.4% of Q32 Bio Inc.'s common stock.
-
Dilution from Recent Offering
The decrease in percentage ownership is due to an increase in the total number of outstanding shares, resulting from the company's recent dilutive capital raise.
Analysis
This Schedule 13D/A filing updates OrbiMed's beneficial ownership in Q32 Bio Inc. The decrease in percentage ownership from an unspecified prior level to 15.4% is explicitly attributed to an increase in the number of outstanding shares, rather than a sale by OrbiMed. This change reflects the dilutive effect of the company's recent $10.5 million offering, which was reported in the 8-K and 10-K filings on March 10, 2026. While OrbiMed remains a significant shareholder, this passive dilution highlights the impact of the company's capital-raising activities on existing investor stakes.
At the time of this filing, QTTB was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $103M. The 52-week trading range was $1.35 to $7.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.